Adverum Biotechnologies Net Change in Intangible Assets 2013-2025 | ADVM

Adverum Biotechnologies net change in intangible assets from 2013 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Adverum Biotechnologies Net Change in Intangible Assets 2013-2025 | ADVM

Adverum Biotechnologies net change in intangible assets from 2013 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$243.4B
Amgen (AMGN)$156.3B
Gilead Sciences (GILD)$147.7B
Vertex Pharmaceuticals (VRTX)$100.1B
Bristol Myers Squibb (BMY)$97.3B
CSL (CSLLY)$85B
GSK (GSK)$80B
Regeneron Pharmaceuticals (REGN)$60B
Alnylam Pharmaceuticals (ALNY)$58B
Argenex SE (ARGX)$39.9B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.4B
Genmab (GMAB)$14.7B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8B
Halozyme Therapeutics (HALO)$7.7B